Boston Pharmaceuticals Inc.
http://www.bostonpharmaceuticals.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boston Pharmaceuticals Inc.
Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
Say Goodbye To NASH And Hello To MASH
The revised nomenclature of metabolic dysfunction-associated steatohepatitis (MASH), rather than non-alcoholic steatohepatitis (NASH), appears to be taking hold among stakeholders in the liver disease space.
Akero’s 96-Week Fibrosis Data Sparkle In MASH
Akero’s Phase IIb study of FGF21 analog efruxifermin demonstrates long-term reduction or resolution of fibrosis, but concerns about bone mineral density declines may confound the data.
Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks
The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice